Blocking sclerostin can promote the expression of osteoblast marker molecules by activating the Wnt/β-catenin pathway and can inhibit the expression of osteoclast differentiation and bone resorption markers, thereby maintaining the dynamic balance between osteoblasts and osteoclasts, and ultimately counteracting osteoporosis (Figure 3). This evidence concerns the gene SOST and osteoporosis.